374 related articles for article (PubMed ID: 30617777)
1. Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease.
Mandal A; Gote V; Pal D; Ogundele A; Mitra AK
Pharm Res; 2019 Jan; 36(2):36. PubMed ID: 30617777
[TBL] [Abstract][Full Text] [Related]
2. Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits.
Weiss SL; Kramer WG
J Ocul Pharmacol Ther; 2019 Sep; 35(7):395-402. PubMed ID: 31355703
[No Abstract] [Full Text] [Related]
3. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis.
Karpecki P; Barghout V; Schenkel B; Huynh L; Khanal A; Mitchell B; Yenikomshian M; Zanardo E; Matossian C
BMC Ophthalmol; 2023 Nov; 23(1):443. PubMed ID: 37919692
[TBL] [Abstract][Full Text] [Related]
4. Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies.
Yu Y; Chen D; Li Y; Yang W; Tu J; Shen Y
Drug Deliv; 2018 Nov; 25(1):888-899. PubMed ID: 29631468
[TBL] [Abstract][Full Text] [Related]
5. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
[TBL] [Abstract][Full Text] [Related]
6. The Effect of OTX-101 on Tear Production in Patients with Severe Tear-deficient Dry Eye Disease: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.
Toyos M; Gupta PK; Mitchell B; Karpecki P
Curr Eye Res; 2022 Feb; 47(2):220-224. PubMed ID: 34459350
[TBL] [Abstract][Full Text] [Related]
7. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye.
Tang-Liu DD; Acheampong A
Clin Pharmacokinet; 2005; 44(3):247-61. PubMed ID: 15762768
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine 0.09% solution (Cequa) for dry eye Disease.
Med Lett Drugs Ther; 2019 Jul; 61(1577):116-118. PubMed ID: 31381551
[No Abstract] [Full Text] [Related]
9. Silk Fibroin Formed Bioadhesive Ophthalmic Gel for Dry Eye Syndrome Treatment.
Hao T; Tang L; Xu Q; Wang W; Li Z; Shen Y; Xu B; Luo H; Li Q; Wang J; Zhang J
AAPS PharmSciTech; 2024 Apr; 25(5):92. PubMed ID: 38684590
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine Amicellar delivery system for dry eyes.
Kang H; Cha KH; Cho W; Park J; Park HJ; Sun BK; Hyun SM; Hwang SJ
Int J Nanomedicine; 2016; 11():2921-33. PubMed ID: 27382280
[TBL] [Abstract][Full Text] [Related]
11. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R
Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591
[TBL] [Abstract][Full Text] [Related]
12. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
[TBL] [Abstract][Full Text] [Related]
13. Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials.
Smyth-Medina R; Johnston J; Devries DK; Jasper A; Kannarr SR; Schechter BA; Shen Lee B; Varghese G; Ogundele A; Darby CH; Karpecki P; Luchs J
J Ocul Pharmacol Ther; 2019 Sep; 35(7):388-394. PubMed ID: 31373837
[No Abstract] [Full Text] [Related]
14. Development and characterization of Cyclosporine A loaded nanoparticles for ocular drug delivery: Cellular toxicity, uptake, and kinetic studies.
Aksungur P; Demirbilek M; Denkbaş EB; Vandervoort J; Ludwig A; Unlü N
J Control Release; 2011 May; 151(3):286-94. PubMed ID: 21241752
[TBL] [Abstract][Full Text] [Related]
15. Exploring the Therapeutic Potential of Cyclosporine for Ophthalmic Indications by Novel Carrier Systems.
Rawat G; Kolhe S; Rana D; Salave S; Benival D
Crit Rev Ther Drug Carrier Syst; 2023; 40(5):1-45. PubMed ID: 37522548
[TBL] [Abstract][Full Text] [Related]
16. Keratitis in Dry Eye Disease and Topical Ciclosporin A.
Leonardi A; Flamion B; Baudouin C
Ocul Immunol Inflamm; 2017 Aug; 25(4):577-586. PubMed ID: 28146363
[TBL] [Abstract][Full Text] [Related]
17. Antiinflammatory therapy for dry eye.
Pflugfelder SC
Am J Ophthalmol; 2004 Feb; 137(2):337-42. PubMed ID: 14962426
[TBL] [Abstract][Full Text] [Related]
18. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
[TBL] [Abstract][Full Text] [Related]
19. A Review of Topical Cyclosporine A Formulations-A Disease-Modifying Agent for Keratoconjunctivitis Sicca.
Jerkins GW; Pattar GR; Kannarr SR
Clin Ophthalmol; 2020; 14():481-489. PubMed ID: 32109984
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome.
Kim HS; Kim TI; Kim JH; Yoon KC; Hyon JY; Shin KU; Choi CY
J Ocul Pharmacol Ther; 2017 Sep; 33(7):530-538. PubMed ID: 28759302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
